Efficacy and safety of anti-PD-1 drugs nivolumab and pembrolizumab in patients with advanced melanoma and preexisting autoimmune disorders or major immune related adverse events with ipilimumab

Trial Profile

Efficacy and safety of anti-PD-1 drugs nivolumab and pembrolizumab in patients with advanced melanoma and preexisting autoimmune disorders or major immune related adverse events with ipilimumab

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Sep 2016

At a glance

  • Drugs Nivolumab (Primary) ; Pembrolizumab (Primary) ; Ipilimumab
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Jul 2016 New trial record
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top